FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study

BACKGROUND: UGT1A1 *28 and *6 polymorphism is associated with reduced enzyme activity and severe toxicities of irinotecan, especially in patients with homozygous or heterozygous for UGT1A1*28 or *6 polymorphism for both UGT1A1*28 and *6 (double-variant-type of UGT1A1 polymorphism, UGT1A1-DV). FOLFIR...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemoto, Kumiko, Takahashi, Hideaki, Morizane, Chigusa, Yamada, Ikuhiro, Shimizu, Satoshi, Shioji, Kazuhiko, Yoshida, Yukio, Motoya, Masayo, Mizuno, Nobumasa, Kojima, Yasushi, Terashima, Takeshi, Uesugi, Kazuhiro, Ueno, Makoto, Furuse, Junji, Akimoto, Tetsuo, Ikeda, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889544/
https://www.ncbi.nlm.nih.gov/pubmed/33386925
http://dx.doi.org/10.1007/s00280-020-04206-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889544/
https://www.ncbi.nlm.nih.gov/pubmed/33386925
http://dx.doi.org/10.1007/s00280-020-04206-w

Ejemplares similares